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Juvenile Dermatomyositis: A Longitudinal Cohort Study and 
Multicohort Validation
Judith Wienke,1 Felicitas Bellutti Enders,2 Johan Lim,3  Jorre S. Mertens,4 Luuk L. van den Hoogen,1  
Camiel A. Wijngaarde,1 Joo Guan Yeo,5 Alain Meyer,6 Henny G. Otten,1 Ruth D. E. Fritsch-Stork,7  
Sylvia S. M. Kamphuis,8 Esther P. A. H. Hoppenreijs,9 Wineke Armbrust,10 J. Merlijn van den Berg,11  
Petra C. E. Hissink Muller,12 Janneke Tekstra,1 Jessica E. Hoogendijk,1 Claire T. Deakin,13  Wilco de Jager,1  
Joël A. G. van Roon,1 W. Ludo van der Pol,1 Kiran Nistala,14 Clarissa Pilkington,14 Marianne de Visser,3 
Thaschawee Arkachaisri,5 Timothy R. D. J. Radstake,1 Anneke J. van der Kooi,3 Stefan Nierkens,1  
Lucy R. Wedderburn,13 Annet van Royen-Kerkhof,1 and Femke van Wijk1
Objective. Objective evaluation of disease activity is challenging in patients with juvenile dermatomyositis (DM) 
due to a lack of reliable biomarkers, but it is crucial to avoid both under- and overtreatment of patients. Recently, 
we identified 2 proteins, galectin- 9 and CXCL10, whose levels are highly correlated with the extent of juvenile DM 
disease activity. This study was undertaken to validate galectin- 9 and CXCL10 as biomarkers for disease activity in 
juvenile DM, and to assess their disease specificity and potency in predicting the occurrence of flares.
Methods. Levels of galectin- 9 and CXCL10 were measured by multiplex immunoassay in serum samples from 
125 unique patients with juvenile DM in 3 international cross- sectional cohorts and a local longitudinal cohort. The 
disease specificity of both proteins was examined in 50 adult patients with DM or nonspecific myositis (NSM) and 61 
patients with other systemic autoimmune diseases.
Results. Both cross- sectionally and longitudinally, galectin- 9 and CXCL10 outperformed the currently used lab-
oratory marker, creatine kinase (CK), in distinguishing between juvenile DM patients with active disease and those in 
remission (area under the receiver operating characteristic curve [AUC] 0.86–0.90 for galectin- 9 and CXCL10; AUC 
0.66–0.68 for CK). The sensitivity and specificity for active disease in juvenile DM was 0.84 and 0.92, respectively, for 
galectin- 9 and 0.87 and 1.00, respectively, for CXCL10. In 10 patients with juvenile DM who experienced a flare and 
were prospectively followed up, continuously elevated or rising biomarker levels suggested an imminent flare up to 
several months before the onset of symptoms, even in the absence of elevated CK levels. Galectin- 9 and CXCL10 
distinguished between active disease and remission in adult patients with DM or NSM (P = 0.0126 for galectin-9 and 
P < 0.0001 for CXCL10) and were suited for measurement in minimally invasive dried blood spots (healthy controls 
versus juvenile DM, P = 0.0040 for galectin-9 and P < 0.0001 for CXCL10).
Conclusion. In this study, galectin- 9 and CXCL10 were validated as sensitive and reliable biomarkers for disease 
activity in juvenile DM. Implementation of these biomarkers into clinical practice as tools to monitor disease activity 
and guide treatment might facilitate personalized treatment strategies.
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INTRODUCTION
Juvenile dermatomyositis (DM) is a rare, chronic systemic 
immune- mediated disease with a high disease burden. In children 
with juvenile DM, the disease is characterized by inflammation of 
the skeletal muscles and skin, leading to muscle weakness and a 
pathognomonic skin rash. Vital organs such as the lung and heart 
can also be involved. Although the pathogenesis is still largely 
unknown, environmental and genetic factors may predispose chil-
dren to the disease (1–5). The autoimmune process is character-
ized by a type I interferon signature and by infiltration of immune 
cells such as plasmacytoid dendritic cells, B cells, CD4+ T cells, 
and macrophages into the skin and muscle tissue (6–9).
Children with juvenile DM are at risk of both under- and 
overtreatment due to a lack of reliable biomarkers that could be 
used to gauge the extent of disease activity. Current treatment 
guidelines recommend immunosuppression for at least 2 years, 
tapering steroids over the first year, and withdrawing treatment if 
a patient has been taken off steroids and has achieved disease 
remission with methotrexate (or an alternative disease- modifying 
antirheumatic drug) for a minimum of 1 year (10–12). However, 
for some patients, this standardized regimen may not be optimal. 
Approximately 50% of patients do not respond to initial treatment 
or present with disease flares during follow- up, resulting in addi-
tional tissue damage and impaired physical recovery (13–15). 
Of the other 50% of patients, some could likely benefit from a 
shorter treatment duration, taking into account that overtreatment 
with steroids can result in serious side effects in children, such 
as Cushing’s syndrome, osteoporosis, and growth delay (16–18).
To determine the rate of medication tapering and to avoid 
both under- and overtreatment, objective measurement of disease 
activity and subclinical inflammation is crucial. However, validated 
and reliable biomarkers for disease activity in juvenile DM are lack-
ing (19). Disease activity is currently assessed by a combination of 
muscle enzyme testing and clinical evaluation (10,20–22); the lat-
ter depends on the experience of the health care professional and 
the patient’s collaboration. Muscle enzymes, including serum cre-
atine kinase (CK) activity, have been shown to correlate only mod-
erately with disease activity in juvenile DM, and the erythrocyte 
sedimentation rate and C- reactive protein level are rarely  elevated 
in patients with juvenile DM (23–25). Lack of objective tools or bio-
markers to monitor the response to therapy also hampers clinical 
trial design. Thus, there is an unmet need for an objective and 
reliable measure of disease activity.
Recently, in a cross- sectional cohort of patients with juvenile 
DM, we demonstrated that 3 proteins, galectin- 9, CXCL10, and 
tumor necrosis factor receptor type II, can distinguish between 
juvenile DM patients with active disease and those in remission, 
with galectin- 9 and CXCL10 being the most discriminative mark-
ers (26,27). CXCL10 and galectin- 9 can be produced by a vari-
ety of cells, both immune and nonimmune, upon stimulation with 
interferons (28,29). CXCL10 has been recognized as a biomarker 
in several human autoimmune diseases, including myositis (29–
33), whereas galectin- 9 has been investigated mainly as a bio-
marker in cancer and viral infections (28,34). Reports on the role 
of galectin- 9 in autoimmunity are conflicting, suggesting either an 
attenuating or an aggravating effect on autoimmune manifesta-
tions in experimental models (35,36). Its role in human autoim-
mune diseases has yet to be elucidated.
We aimed to validate galectin- 9 and CXCL10 as biomarkers 
for active disease in patients with juvenile DM, to examine their 
disease specificity in adult patients with DM, adult patients with 
nonspecific myositis (NSM), and patients with other systemic 
autoimmune diseases, to assess their potency in predicting flares, 
and to test the applicability of the biomarkers in minimally invasive 
dried blood spots, in order to aid broad implementation into clin-
ical practice.
PATIENTS AND METHODS
Cohorts. In total, 125 unique patients with juvenile DM from 
3 independent cross- sectional international cohorts and 1 Dutch 
prospective cohort participated in the present study, with inclusion 
between May 2001 and May 2017. Two large cohorts from Utre-
cht, The Netherlands and London, UK were used for validation of 
the biomarkers; a third smaller cohort from Singapore was used 
to assess international generalizability. An overview of all cohorts 
is shown in Table  1. The internal validation cohort (IVC) from 
Utrecht does not overlap with the previously reported discovery 
cohort (26). For specific questions, including disease specificity, 
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longitudinal follow- up, and measurements in dried blood spots, a 
 combination of blood samples from the IVC and blood samples 
from new patients was used.
Participants. Patients with juvenile DM were included 
if they met the Bohan and Peter criteria for definite or probable 
juvenile DM (37,38). The Childhood Myositis Assessment Scale 
(CMAS; scale 0–52) (39), Manual Muscle Testing of 8 muscle 
groups (MMT- 8; scale 0–80) (40), and physician’s global assess-
ment of disease activity (PhGA; scale 0–10) were recorded as clin-
ical measures of muscle and global disease activity. In addition, 
cutaneous assessment tool (CAT) scores measuring the severity 
of skin disease (scale 0–116) (41)  were recorded in Dutch and 
Singaporean patients. Disease remission was defined according 
to the updated criteria for clinically inactive disease and, in the 
case of missing data, was defined by clinical description (42). 
All other patients were considered to have active disease. Flares 
were defined as the combination of the following 3 items: a pre-
vious response to treatment with the decision to start tapering 
steroids, worsening of at least 1 of 3 clinical scores (CMAS, PhGA, 
and CAT) by ≥2 points, and the decision to start new immunosup-
pressive treatment or increase the current dose.
Adult patients with DM and those with NSM were classified 
according to the European Neuromuscular Centre criteria (43). 
Myositis was confirmed by biopsy unless typical skin manifesta-
tions of DM were present. Patients with cancer- associated myosi-
tis were excluded. Disease activity was determined by combined 
evaluation of muscle strength with the Medical Research Council 
Muscle Scale (44),  skin symptoms, and muscle enzyme levels. 
To determine the disease specificity of the biomarkers, different 
disease controls were added in the study, including pediatric and 
adult patients with systemic lupus erythematosus (SLE), pediatric 
patients with localized scleroderma, adult patients with eosino-
philic fasciitis (EF), and pediatric and adult patients with hereditary 
proximal spinal muscular atrophy (SMA). All controls had either 
systemic inflammation, inflammation of the skin or muscles, or a 
noninflammatory neuromuscular disorder.
Patients with SLE fulfilled the American College of Rheu-
matology classification criteria for SLE (45). Active disease was 
defined as an SLE Disease Activity Index score of ≥4 of 105 (46). 
Patients with localized scleroderma were diagnosed based on the 
typical clinical picture, with active disease being defined as a mod-
ified Localized Scleroderma Skin Severity Index (mLoSSi) score 
of ≥5 of 162 (47). Patients with EF were diagnosed based on the 
clinical picture and histopathologic evaluation of skin biopsy spec-
imens containing the fascia. As the mLoSSi may stay high in these 
patients due to the presence of extensive, irreversible sclerosis 
despite a reduction of inflammation, active disease was defined as 
a PhGA score of ≥5 (on 100- mm visual analog scale) (47). Patients 
with hereditary proximal SMA, a progressive, noninflammatory 
Table 1. Overview of the juvenile DM cohorts*
Abbreviation City, country
No. of 
patients
No. of  
samples
No. of active  
disease–remission 
paired samples
International  
validation cohorts
External validation 
cohort
EVC London, UK 61 79 16
Internal validation 
cohort
IVC; JDM NL Utrecht, The 
Netherlands
47; 47 83; 58 26; 11
Asian cohort JDM Sing Singapore 12 13 –
Analysis- specific sub-
cohorts from Utrecht
Systemic  
autoimmune  
disease cohort
– Utrecht, The 
Netherlands
14 16 2
Longitudinal cohort – Utrecht, The 
Netherlands
28 286 –
Dried blood spot 
cohort
– Utrecht, The 
Netherlands
7 10 –
* Data are listed as follows: for the London external validation cohort (EVC), see Figure 1, Supplementary Table 1, and 
Supplementary Figure 1; for the Utrecht internal validation cohort (IVC), see Figure 1, Supplementary Table 2, and 
Supplementary Figure 1; for the Juvenile Dermatomyositis The Netherlands (JDM NL) and Juvenile Dermatomyositis 
Singapore (JDM Sing) cohorts, see Figure 2 and Supplementary Table 4; for the systemic autoimmune disease cohort, 
see Figure 2 and Supplementary Table 5; for the longitudinal cohort, see Figure 3, Supplementary Table 6, and Sup-
plementary Figure 2; for the dried blood spot cohort, see Figure 4 and Supplementary Table 7. All supplementary 
tables and figures are available on the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.40881/ abstract. 
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neuromuscular disorder, were diagnosed by genetic confirmation 
of a homozygous loss of function of the survival motor neuron 1 
gene (48); these patients served as disease controls. Adult healthy 
volunteers were included as healthy controls.
Ethics approval. The study was approved by the institutional 
ethics committees of the involved centers (UMC Utrecht [approval 
nos. METC 15- 191 and 12- 466], UK [approval no. MREC1/3/22], 
CHUV Lausanne, CHU Strasbourg, SingHealth centralized IRB, 
AMC Amsterdam) and conducted according to the Declaration of 
Helsinki. Written informed consent was obtained prior to inclusion 
in the study, both from patients and from parents or legal repre-
sentatives when the patient was younger than 12 years old.
Blood samples. Blood was collected in serum tubes in 
accordance with the local study protocol (all participating centers). 
At the UMC Utrecht, blood samples were collected in sodium- 
heparin tubes in addition to serum tubes. All samples were spun 
down and aliquoted within 4 hours after collection, and subse-
quently stored at −80°C until analyzed.
Measurement in dried blood spots. Dried blood spots 
were made by application of 50 μl sodium- heparin full blood to 
each spot on Whatman 903 filter paper within 4 hours after the 
blood sample was obtained. Spotted filter papers were dried for 2 
days at room temperature to mimic mail delivery times, and sub-
sequently stored with desiccant in individual air- tight polyethylene 
bags at −80°C under constant monitoring of humidity levels until 
analyzed. Two circles of 3.0 mm in diameter (containing ~3 μl of 
whole blood each) were punched from the central part of 1 spot 
and eluted in 100 μl buffer (phosphate buffered saline contain-
ing 5 ml/liter Tween 20, 10 gm/liter bovine serum albumin, and 
Complete protease inhibitor cocktail with EDTA [1 tablet per 25 ml 
buffer; Roche]) in 96- well plates. Plates were sealed and placed 
overnight at 4°C on a microshaker (600 revolutions per minute) 
and were spun down at 2,100g for 2 minutes. The analysis was 
performed on the obtained eluate.
Biomarker analysis. Galectin- 9 and CXCL10 were 
measured in 50 μl of serum, plasma, or eluate by multiplex assay 
(xMAP; Luminex). CXCL10 was measured in undiluted mate-
rial. Galectin- 9 was measured in 10× diluted plasma or serum, 
except in the serum/plasma samples paired with dried blood 
spots (in which case galectin- 9 was measured undiluted from 
the eluate and serum/plasma). The multiplex immunoassay was 
performed as described previously (49). Heterophilic immuno-
globulins were preabsorbed from all samples with HeteroBlock 
(Omega Biologicals). Acquisition was performed with a Bio- Rad 
FlexMAP3D in combination with xPONENT software version 4.2 
(Luminex). Data analysis was performed with Bioplex Manager 
version 6.1.1 (Bio- Rad).
Between measurement of the internal and external vali-
dation cohorts in 2015, the recombinant protein for galectin- 9 
was replaced, which affected the standard curve. Therefore, 
absolute values between these cohorts may not be compa-
rable. Since 2015, the interassay variability has been negligi-
ble (50). All biomarker analyses were performed at the UMC 
Utrecht, thereby minimizing intercenter variation. Treating 
physicians were blinded with regard to biomarker levels, and 
technicians performing the multiplex assay were blinded with 
regard to clinical data.
Statistical analysis. Basic descriptive statistics were 
used to describe the patient population. Statistical analyses 
were performed using either GraphPad Prism version 7.0 or 
SPSS Statistics version 21 (IBM). Correlations were assessed 
using Spearman’s rank correlation coefficients. For comparisons 
between 2 groups, the Mann- Whitney U test (unpaired analysis) 
or Wilcoxon’s matched- pairs signed rank test (paired analysis) 
was used. For comparisons between multiple groups, nonpara-
metric variants of analysis of variance (ANOVA) with post hoc 
correction for multiple testing were used (Dunn’s post hoc test 
for Kruskal- Wallis, and Šídák’s or Tukey’s post hoc test for 2- way 
ANOVA, as appropriate). Multiplicity- adjusted P values less than 
0.05 were considered significant.
To assess diagnostic accuracy, area under the receiver oper-
ating characteristic (ROC) curves (AUCs) were constructed. Cut-
off values for the diagnostic accuracy of galectin- 9 and CXCL10 
were determined based on the maximal Youden’s Index, with a 
sensitivity of at least 80%.
RESULTS
Cross- sectional validation of galectin- 9 and 
CXCL10. To validate the biomarker potential of galectin- 9 
and CXCL10, we measured the proteins in blood samples 
from patients with juvenile DM from 2 independent validation 
cohorts: an external validation cohort (EVC) from London and 
an internal validation cohort (IVC) from Utrecht. The clinical 
characteristics of these cohorts are shown in Supplementary 
Tables 1 and 2 (available on the Arthritis & Rheumatology web 
site at http://onlin elibr ary.wiley.com/doi/10.1002/art.40881/ 
abstract). As observed in the previously reported discovery 
cohort (26), the levels of galectin- 9 and CXCL10 were sig-
nificantly higher in patients with active disease compared to 
patients in remission (P < 0.0001) (results in Supplementary 
Figures 1A and B [http://onlin elibr ary.wiley.com/doi/10.1002/
art.40881/ abstract]). The levels were highest at the time of 
diagnosis (before treatment), decreased steadily under treat-
ment, and were comparably low in remission regardless of 
whether the patient was receiving or not receiving medication 
while in remission (Figures 1A and B).
GALECTIN- 9 AND CXCL10 AS BIOMARKERS FOR JUVENILE DM |      1381
The wide range of biomarker levels in the group of juvenile 
DM patients with active disease who were on treatment cor-
responded to a wide range of clinical disease activity scores 
within this group (CMAS scores ranging 3–44 in the EVC and 
10–52 in the IVC; PhGA scores ranging 2–8 in the EVC and 
1–9 in the IVC). Based on the levels of both galectin- 9 and 
CXCL10, we were able to differentiate patients with active 
disease while receiving medication from patients in remission 
while receiving medication (Figures 1A and B), which is clinically 
important to assess the response to treatment. Paired analysis 
within individual patients, in which we compared samples from 
a period of active disease and from a period of remission in 
each patient, showed decreasing biomarker levels in response 
to therapy and confirmed the high discriminative power of both 
proteins (each P = 0.0078 in the EVC and P = 0.0002 in the 
IVC) (Figures 1C and D).
To further assess the discriminative power of galectin- 9 and 
CXCL10 for distinguishing between a status of active disease and 
a status of remission in juvenile DM, we examined the AUCs in the 
2 separate cohorts. In comparing active disease and remission in 
patients regardless of their treatment status, the levels of galec-
tin- 9 and CXCL10 had AUCs of 0.894 and 0.863, respectively, in 
Figure  1. Cross- sectional validation of galectin- 9 and CXCL10 as biomarkers for disease activity in juvenile dermatomyositis (DM) in 2 
independent validation cohorts. A and B, Measurement of galectin- 9 and CXCL10 by multiplex immunoassay in serum from patients with active 
disease before start of treatment (group A), active disease while receiving medication (group AM), in remission while receiving medication (group 
RM), and in remission while not receiving medication (group R), in the external validation cohort (EVC) (n = 12 group A, n = 27 group AM, n = 28 
group RM, n = 12 group R) (A) and the internal validation cohort (IVC) (n = 25 group A, n = 30 group AM, n = 16 group RM, n = 12 group R) (B). In 
group AM, 3 samples from 1 patient (from different time points at least 3 months apart) and 2 samples from 6 patients (from different time points 
2–11 months apart) were included. Data are shown as box plots. Each box represents the interquartile range. Lines inside the boxes represent 
the median (log scale). Lines outside the boxes represent the 10th and 90th percentiles. Symbols represent individual patients. Multiplicity- 
adjusted P values were determined by Kruskal- Wallis test with Dunnett’s post hoc test. C and D, Measurement of galectin- 9 and CXCL10 
in paired samples from individual patients (regardless of treatment status) during active disease and remission, from the EVC (median time 
between samples 23 months) (C) and IVC (median time between samples 12 months) (D). P values were determined by Wilcoxon’s matched- 
pairs signed rank test. E and F, Area under the receiver operating characteristic (ROC) curves (AUCs) for diagnostic accuracy of galectin- 9, 
CXCL10, and creatine kinase (CK) in patients (regardless of treatment status) from the EVC (E) and IVC (F). Only patients with complete data for 
the specific ROC curve were included. G and H, Spearman’s rank correlations of galectin- 9, CXCL10, and CK levels with Childhood Myositis 
Assessment Scale (CMAS) scores in the EVC (n = 79) (G) and IVC (n = 61) (H). 
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the EVC and 0.877 and 0.902, respectively, in the IVC (Figures 1E 
and F, and Supplementary Table 3 [online at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40881/ abstract]).
To take into account the effect of treatment, we also 
assessed the AUC for differentiating active disease from dis-
ease remission in patients who were taking medication. Dur-
ing treatment, the levels of galectin- 9 and CXCL10 had AUCs 
of 0.844 and 0.776, respectively, in the EVC and 0.860 and 
0.840, respectively, in the IVC (see Supplementary Figures 1C 
and D and Supplementary Table 3 [http://onlin elibr ary.wiley.
com/doi/10.1002/art.40881/ abstract]). Moreover, galectin- 9 
and CXCL10 performed better than the current standard labo-
ratory marker, CK, in both cohorts (AUCs for CK, 0.682 in the 
EVC and 0.662 in the IVC).
To calculate the optimal cutoff value for distinguishing active 
disease from disease remission, we analyzed the ROC curves 
in the IVC, as blood samples from this cohort were assessed 
according to the most recently optimized and standardized pro-
tocol of the multiplex immunoassay (50). Based on the coordi-
nates of this ROC curve, we determined the cutoff values for 
discriminating active disease from remission, yielding a cutoff 
value of 19,396 pg/ml for galectin- 9 and 805 pg/ml for CXCL10, 
with a high sensitivity (0.84 for galectin- 9 and 0.87 for CXCL10) 
and a high negative predictive value (0.83 for galectin- 9 and 0.87 
for CXCL10) (Table 2); these values ensured a low risk of ongo-
ing inflammation in the case of a test result that was below the 
cutoff. The specificity of the galectin- 9 and CXCL10 cutoff lev-
els was 0.92 and 1.00, respectively, and the positive predictive 
value was 0.93 and 1.00, respectively.
Consistent with the previously reported discovery cohort 
(26), the levels of galectin- 9 and CXCL10 correlated strongly 
with 3 clinical scores of global or muscle disease activity: the 
PhGA, the CMAS, and the MMT- 8. The correlation coefficients 
for association with either of the biomarkers, which ranged 
between 0.67 and 0.81 (P < 0.0001), were notably higher than 
those for CK (rs = 0.32–0.51, P < 0.01) (Figures  1G and H, 
and Supplementary Figures 1E–G [http://onlin elibr ary.wiley.
com/doi/10.1002/art.40881/ abstract]). Thus, these results 
in 2 independent validation cohorts validate galectin- 9 and 
CXCL10 as strong biomarkers for disease activity in patients 
with juvenile DM, outperforming the currently used laboratory 
marker CK.
To assess the international generalizability of galectin- 9 and 
CXCL10, we tested the biomarkers in a small cohort of patients 
with juvenile DM from a different geographic region (i.e., Singa-
pore). Observations in this cohort confirmed the discriminative 
potential of galectin- 9 and CXCL10 between active disease and 
remission, and their levels were comparable to those seen in 
the IVC (P = 0.0006 for galectin- 9 and P = 0.0025 for CXCL10) 
(Figures 2A and B).
Disease specificity of galectin- 9 and CXCL10. We next 
investigated the disease specificity of galectin- 9 and CXCL10 
and explored the applicability of each as a biomarker in adult 
patients with DM or NSM and patients with other systemic 
autoimmune diseases. The biomarkers were first measured in a 
cohort of adult patients with DM (n = 36), patients with NSM (n 
= 14), and patients with EF (n = 18), as well as 43 disease con-
trol patients with SMA, a genetic neuromuscular disorder without 
systemic inflammation, and 22 healthy controls (the characteris-
tics of these subjects are listed in Supplementary Table 4 [http://
onlin elibr ary.wiley.com/doi/10.1002/art.40881/ abstract]). The 
levels of both galectin- 9 and CXCL10 were elevated in adult 
patients with active DM (P < 0.0001), patients with NSM (P < 
0.0003), and patients with EF (P < 0.05) as compared to healthy 
controls. Both biomarkers distinguished between active dis-
ease and remission in the adult DM cohort (P = 0.0126 and P < 
0.0001 for galectin- 9 and CXCL10, respectively), and CXCL10 
was also discriminative for disease activity in patients with NSM 
(P = 0.0139) and those with EF (P = 0.0497) (Figures 2A and 
B). As expected, the biomarkers were not elevated in control 
patients with SMA.
A second cohort consisted of pediatric and adult patients 
with 2 other systemic immune- mediated diseases: localized 
scleroderma (n = 15) and SLE (n = 36) (the characteristics of 
these patients are listed in Supplementary Table 5 [http:// 
onlin elibr ary.wiley.com/doi/10.1002/art.40881/ abstract]). In 
patients with localized scleroderma and those with SLE, the 2 
biomarkers did not distinguish significantly between active dis-
ease and remission, but galectin- 9 levels in patients with SLE 
were elevated compared to healthy controls (P = 0.0105) (Fig-
ures 2C and D).
Thus, these results demonstrate that galectin- 9 and 
CXCL10 are applicable as biomarkers for disease activity in both 
pediatric and adult patients with myositis.
Table 2. Sensitivity, specificity, NPV, and PPV of the determined 
cutoff values for diagnostic accuracy of galectin- 9 and CXCL10 in 
the juvenile dermatomyositis internal validation cohort*
Galectin- 9 CXCL10
Cutoff value, pg/ml 19,396 805
Sensitivity 0.839 0.871
Specificity 0.923 1.000
NPV 0.828 0.867
PPV 0.929 1.000
* Cutoff values for galectin- 9 and CXCL10 were determined based 
on the maximal Youden’s Index with a sensitivity of >0.80, in or-
der to ensure a low risk of ongoing active inflammation with a bio-
marker value below the set cutoff. Only 1 sample per patient per 
category (active disease or in remission) was included in the analy-
sis (i.e., the cohort designated “JDM NL” [Juvenile Dermatomyositis 
The Netherlands], as shown in Figure 2 and Supplementary Table 
5 on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.40881/ abstract]). NPV = negative pre-
dictive value; PPV = positive predictive value. 
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Figure 2. Biomarker potential of galectin- 9 and CXCL10 in adult inflammatory myopathies and systemic autoimmune diseases with skin 
involvement. A and B, Galectin- 9 (A) and CXCL10 (B) were measured in serum samples from patients with juvenile dermatomyositis from The 
Netherlands (JDM NL) (the internal validation cohort [IVC]) and Singapore validation cohort (JDM Sing), adult patients with DM, adult patients 
with nonspecific myositis (NSM), adult patients with eosinophilic fasciitis (EF), a mixed cohort of adult and juvenile patients with hereditary 
proximal spinal muscular atrophy (SMA), and adult healthy controls (HC). C and D, Galectin- 9 (C) and CXCL10 (D) were measured in serum 
samples from the Dutch juvenile DM cohort, juvenile patients with localized scleroderma (LoS), a mixed cohort of juvenile and adult patients with 
systemic lupus erythematosus (SLE), and adult healthy controls. In A–D, patients were stratified into 2 groups based on disease activity (active 
[A] or in remission [R] regardless of treatment status). Only 1 sample per patient per activity group was included in the analysis; therefore, the 
numbers of patients in the IVC differ from those in Figure 1. Data are shown as box plots. Each box represents the interquartile range. Lines 
inside the boxes represent the median (log scale). Lines outside the boxes represent the 10th and 90th percentiles. Symbols represent individual 
patients. Multiplicity- adjusted P values above boxes are for comparison between active disease and remission, by 2- way analysis of variance 
with Šídák’s post hoc test for multiple comparisons. Multiplicity- adjusted P values below boxes are for comparison between each disease group 
and healthy controls, by Kruskal- Wallis test with Dunnett’s post hoc test for multiple comparisons. P values >0.999 are not shown.
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Prospective analysis and flare prediction. To deter-
mine the prognostic value of galectin- 9 and CXCL10 during 
clinical follow- up in patients with juvenile DM, we measured 
the biomarkers in a prospective cohort of 28 patients, with a 
median follow- up time of 2.8 years per patient (the charac-
teristics of these patients are listed in Supplementary Table 6 
[http://onlin elibr ary.wiley.com/doi/10.1002/art.40881/ abstract]). 
First, we established the biomarker dynamics after diagnosis 
in 15 patients who reached sustained remission within the first 
months of treatment and did not have a flare later. The biomarker 
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Figure 3. Galectin- 9 and CXCL10 serum levels from longitudinal follow- up of patients with juvenile dermatomyositis (DM) in a prospective cohort. 
A and B, Dynamics of galectin- 9 (A) and CXCL10 (B) serum levels up to 6 years after juvenile DM diagnosis in 15 patients without flares. The first 
sample was obtained a maximum of 6 months after treatment start. Both patients with and those without intensification of therapy within the first 
3 months were included. Each point contains between 3 and 13 samples, pooled over the time span around the data point. The median interval 
between 2 samples from a patient was 3.6 months. Per patient, 4–14 samples (median 9) were included. Values are the mean ± SD (linear scale). 
C and D, Galectin- 9 (C) and CXCL10 (D) serum levels in longitudinal samples from juvenile DM patients with a flare within the first year (<12m) (n = 
6), after the first year (>12m) (n = 7), or without flares (n = 15) (same patients as in A and B). Only patients with a first sample obtained a maximum 
of 6 months after treatment start were included. Left, Longitudinal data (mean ± SD) within the first year. Multiplicity- adjusted P values, by 2- way 
analysis of variance (ANOVA) with Tukey’s post hoc test, were for flare <12 months versus no flare (top) or flare <12 months versus flare >12 
months (bottom) Middle, Galectin- 9 and CXCL10 levels at diagnosis, before treatment start. Data are shown as box plots. Boxes represent the 
interquartile range, lines inside the boxes show the median, and lines outside the boxes show the 10th and 90th percentiles. Symbols represent 
individual patients. All P values, by 2- way ANOVA with Tukey’s post hoc test, were corrected. Right, Total area under the receiver operating 
characteristic curves (AUCs) for each group, calculated by the trapezoidal method. Values are the mean and 95% confidence interval. P values 
were determined by one- way ANOVA with Tukey’s post hoc test. E, Galectin- 9, CXCL10, and creatine kinase (CK) serum levels in 6 individuals 
with a flare within the first year after treatment start. In A–F, Gray shading indicates the previously determined cutoffs for galectin- 9 and CXCL10 
(19,396 pg/ml and 805 pg/ml, respectively) and the standard cutoff for CK (150 IU/liter). F, Levels of galectin- 9, CXCL10, and CK measured 
longitudinally in an individual with a disease flare after the first year. Broken horizontal lines indicate the previously determined cutoffs for galectin- 9, 
CXCL10, and CK. Biomarker levels are shown on a log scale. Shading in the rows for prednisone (Pred) and methotrexate (MTX) represent the 
relative medication dose (in mg/kg/day for prednisone; in mg/m2/week for MTX). Dark gray shading = high dose; lighter gray shading = low dose. 
Dx = diagnosis; CMAS = Childhood Myositis Assessment Scale; PhGA = physician’s global assessment; CAT = cutaneous assessment tool. 
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levels quickly declined after the start of treatment, reached lev-
els below the previously determined cutoff value within several 
months, and remained low in remission (the “No flare” group, 
shown in Figures 3A and B). The biomarker dynamics in patients 
with a flare after the first year (the “Flare >12 months” group; n 
= 7) were similar to those in patients without flares (Figures 3C 
and D). However, patients who experienced a disease flare in 
the first year after the start of treatment (the “Flare <12 months” 
group; n = 6) had significantly higher biomarker levels at diagno-
sis than did patients with later flares (P = 0.0254 for galectin- 9 
and P = 0.0265 for CXCL10) (Figures 3C and D). In addition, 
these patients who experienced a flare at <12 months had ele-
vated biomarker levels over the entire first year (Figures 3C–E). 
In contrast to the 2 biomarkers, CK activity normalized in 5 of 6 
patients (Figure 3E).
To assess the predictive value of the biomarkers for flares 
after the first year, we analyzed 4 patients for whom longitudinal 
samples were available within 7 months before a flare (Figure 3F 
and Supplementary Figure 2 [http://onlin elibr ary.wiley.com/
doi/10.1002/art.40881/ abstract]). In patients 1 and 2, raised 
levels of galectin- 9 and CXCL10 (even while remaining below 
the cutoff level) were observed from up to 7 months prior to the 
flare, with levels that were above the cutoff value up to 6 months 
prior to the flare for galectin- 9 and up to 3 months prior to the 
flare for CXCL10. These biomarker fluctuations were observed 
even before clinical symptoms of a flare became apparent. 
In patients 3 and 4, persistently borderline cutoff values were 
observed for galectin- 9 and CXCL10 in the 12 months prior to 
occurrence of a flare, and biomarkers were elevated above the 
cutoff during the flare. In contrast, CK levels did not increase 
prior to or during a flare in patient 4, and did not demonstrate 
an increase until the occurrence of a flare in patients 2 and 3. 
Only in patient 1 did the CK level steadily increase by 3 months 
prior to a flare. It was also observed that galectin- 9 and CXCL10 
levels stayed high during continued disease activity after the 
start of the flare in patients receiving medication, while in 3 of 
4 individuals, the CK level decreased to within normal limits by 
the first time point following the start of the clinical flare, despite 
continued disease activity.
Thus, these results suggest that persistently high or rising 
galectin- 9 and CXCL10 levels above their cutoff values may be 
indicative of ongoing (sub)clinical inflammation or an imminent 
flare, even with a lack of clinical symptoms or elevated CK levels.
Levels of galectin- 9 and CXCL10 in dried blood spots. 
To facilitate minimally invasive (at- home) biomarker assessment 
and broad clinical applicability with centralization of diagnostic 
cores, we assessed galectin- 9 and CXCL10 measurements in 
dried blood spots and paired plasma and serum samples (the 
patients’ characteristics are shown in Supplementary Table 7 
[http://onlin elibr ary.wiley.com/doi/10.1002/art.40881/ abstract]). 
Correlation between the biomarker levels in the circulation and 
biomarker levels in dried blood spots was higher for CXCL10 
(rs = 0.93 in plasma and rs = 0.96 in serum) than for galectin- 9 (rs = 
Figure 4. Measurement of galectin- 9 and CXCL10 levels in dried blood spots (DBS) as compared to paired plasma and serum samples from 
patients with active juvenile dermatomyositis (DM). A and B, Correlations between biomarker levels in the plasma (A) and serum (B) and in 
DBS (on a double log scale) were assessed using Spearman’s correlation coefficients. C, Paired representation of the biomarker levels in the 
plasma, serum, and DBS from healthy controls (HC), patients with active juvenile DM pretreatment (JDM A), and patients with active juvenile DM 
while receiving medication (JDM AM) are shown. D, Biomarker levels in DBS were compared between healthy controls and patients with active 
juvenile DM. P values were determined by Mann- Whitney U test.
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0.62 in plasma and rs = 0.58 in serum)  (Figures 4A and B). Galec-
tin- 9 and CXCL10 levels were similar in the plasma and serum 
(Figure 4C). Both galectin- 9 and CXCL10, as measured in dried 
blood spots, were capable of discriminating between patients 
with active juvenile DM and healthy controls (P = 0.0040 and P < 
0.0001, respectively) (Figure 4D), with the healthy control subjects 
having biomarker levels that were similar to those in patients with 
juvenile DM in remission (Figure 2). Thus, measurements of both 
galectin- 9 and CXCL10 in dried blood spots are suitable as bio-
markers for juvenile DM disease activity.
DISCUSSION
In this study, galectin- 9 and CXCL10 were validated as strong, 
reliable, and sensitive biomarkers for disease activity in juvenile 
DM, and both were identified as promising biomarkers both in 
adult patients with DM and in adult patients with NSM. The levels 
of galectin- 9 and CXCL10 strongly distinguished between juvenile 
DM patients with active disease and juvenile DM patients in remis-
sion, even when the patient was receiving immunosuppressive 
treatment. Furthermore, we showed that galectin- 9 and CXCL10 
were relatively specific for autoinflammatory myopathies in adult 
and pediatric patients, as their levels were not as highly increased 
or did not differentiate between active disease and remission in 
other autoimmune diseases such as localized scleroderma and 
SLE. Both cross- sectionally and longitudinally, galectin- 9 and 
CXCL10 outperformed CK, which is commonly used as a labo-
ratory marker for disease activity and is one of the current criteria 
for determining clinically inactive disease in juvenile DM (42,51). 
Continuously elevated or rising biomarker levels, as determined 
in a prospective patient cohort, may be indicative of an imminent 
disease flare up to several months before clinical symptoms, even 
in the absence of elevated CK levels. The biomarkers may there-
fore be promising to use in longitudinal follow- up of patients for 
monitoring of disease activity.
Furthermore, our results showed that galectin- 9 and 
CXCL10 can be reliably measured in the plasma, serum, and 
minimally invasive dried blood spots from patients with juvenile 
DM. It has recently been shown that capillary concentrations of 
CXCL10 correlate with venous concentrations; for galectin- 9, 
this has not yet been established (52). The moderate correlation 
between circulating levels of galectin- 9 and levels of galectin- 9 in 
dried blood spots could be attributed to either liberation of intra-
cellularly stored galectin- 9 and/or release from its carrier proteins 
upon elution and dilution.
This study has several strengths. Although many biomark-
ers are being identified for a variety of diseases, only a few 
have been implemented into clinical practice, due to a lack of 
reproducibility and diagnostic accuracy. However, the levels of 
galectin- 9 and CXCL10 have a high discriminative power and 
strong, reproducible correlation with disease activity. Thanks 
to a large international collaborative effort, and despite the rar-
ity of the disease, we have been able to extensively validate 
galectin- 9 and CXCL10 as biomarkers in a large number of 
patients with juvenile DM from 3 independent cross- sectional 
cohorts. The additional analyses in a prospective cohort of 
patients with juvenile DM with a long follow- up time added 
important information on the value of galectin- 9 and CXCL10 
in clinical follow- up. In addition to the clinical validation in this 
study, the biomarkers have undergone a technical validation 
at the diagnostic department of the UMC Utrecht, which has 
demonstrated the stability of the biomarkers and reproducibil-
ity of the measurements. In addition, we have explored a mini-
mally invasive diagnostic method of measuring the biomarkers 
in dried blood spots.
The findings of this study need to be interpreted carefully, tak-
ing into account the observational nature of the data and the use 
of a combination of clinical scores and CK levels (the Paediatric 
Rheumatology International Trials Organisation criteria for clinically 
inactive disease in juvenile DM) as the gold standard for assess-
ment of disease activity in juvenile DM (42,51). Importantly, mea-
surement of galectin- 9 and CXCL10 levels can complement, but 
not replace, clinical assessment by experienced health care pro-
fessionals. However, both biomarkers outperformed the currently 
used marker, CK, a finding that underscores the gains that can be 
achieved by introducing the new biomarkers into clinical practice.
A recent study using the SOMAscan assay also identified 
both galectin- 9 and CXCL10 among the top up- regulated proteins 
in juvenile DM, correlating with disease activity as assessed by the 
PhGA (53). CXCL10 levels were previously shown to correlate with 
disease activity in juvenile DM (26,30–32,54), and CXCL10 is well 
known to be an interferon- inducible chemokine that can be ele-
vated in other types of myositis and autoimmune diseases (29,33). 
In our study, galectin- 9 was a specific biomarker for inflammatory 
myopathies. In patients with juvenile DM, high circulating interfer-
on- α levels have been found, and in one group of patients with 
juvenile DM, more than 75% of patients had a positive interferon 
signature (55,56). Circulating galectin- 9 and CXCL10 levels could 
therefore be a direct reflection of active, interferon- driven inflam-
mation, which is supported by a recent study in which galectin- 9 
was demonstrated to be a marker for the interferon signature in 
SLE and antiphospholipid syndrome (57).
Since the levels of these biomarkers are known to correlate 
with the extent of disease activity in various types of tissue, local 
tissue cells are the main candidate producers of the proteins. 
Indeed, galectin- 9 can be detected not only in the circulation, but 
also locally within inflamed muscle and skin, where it is mainly 
present in activated tissue macrophages and capillary endothe-
lial cells (data not shown). A similar expression pattern, in tissue 
mononuclear cells and endothelial cells, was previously demon-
strated for CXCL10 (58,59). Local biomarker production within the 
inflamed tissue is consistent with our previous observation that 
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the biomarker levels slowly decline after stem cell transplantation, 
as tissue- infiltrating immune cells (and endothelial cells) are likely 
to be less affected by immune- ablative preconditioning than are 
circulating immune cells (27).
Implementation of galectin- 9 and CXCL10 into clinical prac-
tice, as tools to monitor disease activity and guide treatment, might 
enable personalized treatment strategies for patients with juvenile 
DM. It is an advantage that both biomarkers performed equally well 
in our study, suggesting that diagnostic centers can decide to use 
their biomarker of choice depending on its availability and feasibility. 
Biomarker levels below the set cutoff value reflect the absence of 
disease activity, which could allow tapering of immunosuppressive 
medication. Rising or persistently high levels might be indicative of 
an insufficient response to therapy and/or an imminent flare, even 
in the absence of clinical symptoms or elevated CK levels, possibly 
reflecting subclinical inflammation. Elevated biomarker levels might 
therefore indicate the need for intensification of treatment or slower 
tapering of steroids. With this envisioned personalized treatment 
strategy, we could respond to important patient- reported needs: 
a recently conducted patient survey by Cure JM, a US patient 
organization for juvenile myositis, has shown that “predictors for 
disease flares” and “new treatments, less side effects” are 2 of the 
top  3 research priorities chosen by patients (60).
Galectin- 9 and CXCL10 may also provide an objective out-
come measure for response to therapy in future clinical trials that 
would be assessing novel therapeutics. Our study has shown that 
galectin- 9 and CXCL10 levels in dried blood spots correlate with 
venous levels and could differentiate patients with active juvenile 
DM from healthy controls. Longitudinal assessment of these bio-
markers via dried blood spots, which requires further study, has 
potential for high utility in the future, since dried blood spots can 
be sampled at home by simple capillary finger- prick. Since protein 
levels in dried blood spots remain remarkably stable over time, 
even at room temperature (61,62), samples of dried blood spots 
can be sent to a diagnostic center through regular mail. This 
enables at- home diagnostics and centralization of diagnos-
tic cores for both clinical care and multicenter studies. It also 
ensures maximum accessibility of the biomarker measurements 
for non–expert medical centers, which can also facilitate care in 
rural areas.
Galectin- 9 and CXCL10 measurements could add impor-
tant information to the complex differential diagnosis of mus-
cle symptoms during follow- up, and might aid in discriminating 
between steroid- induced myopathy, noninflammatory muscle 
pain, and muscle inflammation, all of which require different 
treatment strategies. In these complicated cases, in particular, 
the biomarkers may also help abrogate the need for invasive 
diagnostic muscle biopsy or costly magnetic resonance imag-
ing scans, which can sometimes require sedation in young chil-
dren. This specific potential use of these biomarkers will have to 
be further investigated in additional prospective studies. In addi-
tion, future prospective studies will have to point out 1) whether 
one biomarker may be superior to the other in answering spe-
cific clinical questions concerning juvenile DM, 2) whether the 
biomarkers are able to detect mild disease activity, 3) whether 
the biomarkers also have prognostic value in adult patients with 
myositis, and 4) whether biomarker- guided disease manage-
ment will improve the outcomes in patients with juvenile DM.
In conclusion, galectin- 9 and CXCL10 were identified and 
extensively validated as strong, reliable, and sensitive biomark-
ers for disease activity in juvenile DM. Measurement of these 
biomarkers might facilitate personalized treatment strategies for 
patients with juvenile DM, by providing a diagnostic monitoring 
tool to guide treatment.
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